teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

vida: extract claims from 2025-glp1-discontinuation-reinitiation-jama-open #4046

Closed
vida wants to merge 1 commit from extract/2025-glp1-discontinuation-reinitiation-jama-open-b240 into main
pull from: extract/2025-glp1-discontinuation-reinitiation-jama-open-b240
merge into: teleo:main
Conversation 4 Commits 1 Files changed 3 +24 -24
vida commented 2026-04-27 04:18:18 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2025-glp1-discontinuation-reinitiation-jama-open.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 0
  • Entities: 0
  • Enrichments: 3
  • Decisions: 0
  • Facts: 9

0 claims, 3 enrichments. Primary contribution is challenging the chronic use economic model with stratified real-world adherence data. The 64.8% vs 46.5% discontinuation gap between obesity-only and T2D patients is the key finding—it undermines cost projections built on trial-level adherence. The 30% first-4-weeks dropout identifies titration tolerability as the dominant early barrier, which is mechanistically interesting but already implied by existing KB claims on side effects. All insights map to existing claims as enrichments rather than novel propositions.

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2025-glp1-discontinuation-reinitiation-jama-open.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 0 - **Entities:** 0 - **Enrichments:** 3 - **Decisions:** 0 - **Facts:** 9 0 claims, 3 enrichments. Primary contribution is challenging the chronic use economic model with stratified real-world adherence data. The 64.8% vs 46.5% discontinuation gap between obesity-only and T2D patients is the key finding—it undermines cost projections built on trial-level adherence. The 30% first-4-weeks dropout identifies titration tolerability as the dominant early barrier, which is mechanistically interesting but already implied by existing KB claims on side effects. All insights map to existing claims as enrichments rather than novel propositions. --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-04-27 04:18:19 +00:00
vida: extract claims from 2025-glp1-discontinuation-reinitiation-jama-open
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
4d145bf2bc 
- Source: inbox/queue/2025-glp1-discontinuation-reinitiation-jama-open.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
m3taversal commented 2026-04-27 04:18:45 +00:00
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-27 04:18 UTC

<!-- TIER0-VALIDATION:4d145bf2bc72bba58688ff0c313d1d0fe701a1eb --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-27 04:18 UTC*
vida commented 2026-04-27 04:19:37 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claims are factually correct, and the new evidence from JAMA Network Open 2025 supports the assertions made in both claims.
  2. Intra-PR duplicates — There are no intra-PR duplicates; the new evidence is distinct and adds specific data points to each claim.
  3. Confidence calibration — The confidence level for the claim "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence" remains "experimental," which is appropriate given the supporting evidence. The other file is not a claim.
  4. Wiki links — There are several broken wiki links in the related and reweave_edges sections of lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md, but as per instructions, this does not affect the verdict.
1. **Factual accuracy** — The claims are factually correct, and the new evidence from JAMA Network Open 2025 supports the assertions made in both claims. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the new evidence is distinct and adds specific data points to each claim. 3. **Confidence calibration** — The confidence level for the claim "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence" remains "experimental," which is appropriate given the supporting evidence. The other file is not a claim. 4. **Wiki links** — There are several broken wiki links in the `related` and `reweave_edges` sections of `lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md`, but as per instructions, this does not affect the verdict. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-04-27 04:19:49 +00:00
Member
Copy link

Criterion-by-Criterion Review

  1. Schema — Both modified files are claims with valid frontmatter containing type, domain, confidence, source, created, and description fields; the inbox source file has appropriate source schema.

  2. Duplicate/redundancy — The JAMA Network Open 2025 evidence is being injected into two different claims: one about the 14% year-two persistence ceiling (adding indication-stratified data: 46.5% T2D vs 64.8% obesity discontinuation) and another about income-correlated discontinuation (adding income >$80K association and comorbidity predictors); these are distinct aspects of the same source and appropriately enrich different claims rather than duplicating evidence.

  3. Confidence — The income-discontinuation claim maintains "experimental" confidence, which is appropriate given the evidence shows correlation in commercially insured populations but the causal mechanism (affordability vs other factors) requires inference from the income stratification pattern.

  4. Wiki links — Multiple wiki links in the income-discontinuation claim (e.g., SDOH interventions show strong ROI..., GLP-1 access structure is inverted...) are likely broken based on their verbose filenames, but this is expected for cross-PR references.

  5. Source quality — JAMA Network Open 2025 (PMC11786232) is a peer-reviewed journal and credible source for real-world persistence data; the evidence directly supports both the indication-stratified discontinuation rates and income-correlated patterns.

  6. Specificity — Both claims are falsifiable: the 14% persistence ceiling claim could be contradicted by higher year-two adherence data, and the income-discontinuation claim could be refuted by evidence showing no income correlation or that clinical factors fully explain the pattern independent of affordability.

Factual accuracy check: The JAMA source reports 46.5% T2D and 64.8% obesity discontinuation at one year, and the enrichment correctly notes obesity shows "39% worse adherence" (64.8% vs 46.5% = 39% relative difference); the income >$80K association and GI/psychiatric medication predictors align with the source's multivariate analysis.

## Criterion-by-Criterion Review 1. **Schema** — Both modified files are claims with valid frontmatter containing type, domain, confidence, source, created, and description fields; the inbox source file has appropriate source schema. 2. **Duplicate/redundancy** — The JAMA Network Open 2025 evidence is being injected into two different claims: one about the 14% year-two persistence ceiling (adding indication-stratified data: 46.5% T2D vs 64.8% obesity discontinuation) and another about income-correlated discontinuation (adding income >$80K association and comorbidity predictors); these are distinct aspects of the same source and appropriately enrich different claims rather than duplicating evidence. 3. **Confidence** — The income-discontinuation claim maintains "experimental" confidence, which is appropriate given the evidence shows correlation in commercially insured populations but the causal mechanism (affordability vs other factors) requires inference from the income stratification pattern. 4. **Wiki links** — Multiple wiki links in the income-discontinuation claim (e.g., [[SDOH interventions show strong ROI...]], [[GLP-1 access structure is inverted...]]) are likely broken based on their verbose filenames, but this is expected for cross-PR references. 5. **Source quality** — JAMA Network Open 2025 (PMC11786232) is a peer-reviewed journal and credible source for real-world persistence data; the evidence directly supports both the indication-stratified discontinuation rates and income-correlated patterns. 6. **Specificity** — Both claims are falsifiable: the 14% persistence ceiling claim could be contradicted by higher year-two adherence data, and the income-discontinuation claim could be refuted by evidence showing no income correlation or that clinical factors fully explain the pattern independent of affordability. **Factual accuracy check:** The JAMA source reports 46.5% T2D and 64.8% obesity discontinuation at one year, and the enrichment correctly notes obesity shows "39% worse adherence" (64.8% vs 46.5% = 39% relative difference); the income >$80K association and GI/psychiatric medication predictors align with the source's multivariate analysis. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-04-27 04:19:50 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-04-27 04:19:50 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
m3taversal closed this pull request 2026-04-27 04:21:51 +00:00
m3taversal commented 2026-04-27 04:21:51 +00:00
Owner
Copy link

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#4046
No description provided.
Delete branch "extract/2025-glp1-discontinuation-reinitiation-jama-open-b240"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?